> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Allergan, AstraZeneca Partner on Antibiotic Combo
- URL: https://www.fdaweb.com/allergan-astrazeneca-partner-on-antibiotic-combo/
- Published: 2016-02-01T12:00:00.000Z
- Updated: 2026-09-15T02:32:21.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5134627

> Allergan and AstraZeneca have entered into a global agreement to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic containing aztreonam and avibactam. Under the pact, the companies say they will evaluate the combination to treat serious infections caused by *metallo βlactamase* MBL-producing Gram-negative pathogens, a difficult-to-treat sub-type of carbapenem-resistant *Enterobacteriaceae*, which currently have limited treatment options. The agreement calls for Allergan maintaining commercialization rights in the U.S. andCanadaandAstraZenecamaintaining the commercialization rights in all other countries.  
>  
>  
>  
> ATM-AVI is the first drug candidate to be developed under a public-private partnership agreement betweenAstraZenecaand theBiomedical Advanced Research and Development Authority([BARDA](http://www.phe.gov/barda?ref=fdaweb.com)), a part of theU.S. Department of HealthandHuman Services' Office of the Assistant Secretary for Preparedness and Response([ASPR](http://www.phe.gov/?ref=fdaweb.com)). The goal of this strategic alliance is to develop a portfolio of drug candidates over the next five years with dual uses in treating illnesses caused by bioterrorism agents and antibiotic-resistant infections.  
>  
>  
>  
> Aztreonam is not inactivated by MBLs — as a single agent it has limited utility because the vast majority of MBL-producing pathogens also express serine-β-lactamases that can inactivate it, Allergan says. “With avibactam’s ability to inhibit many serine-β-lactamase enzymes, aztreonam’s activity is restored against pathogens that co-produce MBLs and serine enzymes, thus presenting a new treatment option for patients.”